EGFR and non-small cell lung carcinoma: Subsequent analysis by the authors suggested the additional effect of bevacizumab on erlotinib monotherapy for NSCLC with EGFR mutations gradually decreased in the order of PFS2 (28.6 months vs 24.3 months, HR 0.80; 95% CI 0.59–1.10) and overall survival (50.7 months vs 46.2 months, HR 1.00 95% CI 0.68–1.48), with no significant differences.